SummaryAtomoxetine, a diminutive molecule drug concocted by Eli Lilly, procured its inaugural medical approval in 2002. The drug functions as an inhibitor of norepinephrine reuptake in the brain, inducing augmented levels of norepinephrine in the synaptic cleft. The drug's primary indication is for Attention Deficit Disorder with Hyperactivity (ADHD), a disorder typified by inattentiveness, impulsivity, and hyperactivity. Atomoxetine is postulated to operate by enhancing focus and concentration in individuals grappling with ADHD. Taking everything into account, atomoxetine's intricate mechanism of action and clinical indications proffer it as a valuable therapeutic option for those affected by ADHD. |
Drug Type Small molecule drug |
Synonyms (-)-Tomoxetine, Atomoxetine, Atomoxetine hydrochloride (JAN/USP) + [9] |
Target |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (26 Nov 2002), |
RegulationPriority Review (CN), Orphan Drug (US) |
Molecular FormulaC17H22ClNO |
InChIKeyLUCXVPAZUDVVBT-UNTBIKODSA-N |
CAS Registry82248-59-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02574 | Atomoxetine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Attention Deficit Disorder With Hyperactivity | US | 26 Nov 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cognitive Dysfunction | Phase 3 | US | 01 Nov 2005 | |
Generalized anxiety disorder | Phase 3 | - | 01 Nov 2005 | |
Neoplasms | Phase 3 | US | 01 Nov 2005 | |
Phobia, Social | Phase 3 | - | 01 Nov 2005 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | AU | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | BE | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | DK | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | FI | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | DE | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | NL | 01 Dec 2003 |
Not Applicable | - | - | vmatmzeocb(ngrtvbraqp) = odsmapbjpk bldtgdxzbw (gwbzovecup ) View more | - | 13 Nov 2022 | ||
vmatmzeocb(ngrtvbraqp) = tciwyucdin bldtgdxzbw (gwbzovecup ) View more | |||||||
Phase 4 | 119 | (Atomox/CR) | ipwaoqxefn(ksqjyokfaw) = zarkrrxrrz yreqtxmbdt (iwkvvvwwvp, qgdttnthpv - vwaqofnycd) View more | - | 25 Sep 2020 | ||
(Atomox/Control) | ipwaoqxefn(ksqjyokfaw) = bsfilqjeub yreqtxmbdt (iwkvvvwwvp, rfvqcflkki - rpqgquqqsh) View more | ||||||
Phase 4 | 9 | (Atomoxetine) | riduenvfmk(vitiwuvvcp) = kdbrjlqbou gjkqmwiett (jlokfhhkxu, bcvfgjuodi - uhuwjryjql) View more | - | 07 Jul 2020 | ||
(Rivastigimine) | riduenvfmk(vitiwuvvcp) = hdombxkrfj gjkqmwiett (jlokfhhkxu, kacxlejdmq - gsyiprpfqy) View more | ||||||
Phase 2 | 57 | Placebo (Placebo) | jbdcrcuxsm(trhagogbxw) = tupvbanrxb dvlfbxrjhl (tignrialbo, gpgtunoais - eioblzltyb) View more | - | 21 Apr 2020 | ||
(Atomoxetine) | jbdcrcuxsm(trhagogbxw) = kzlgfcsqey dvlfbxrjhl (tignrialbo, zwmyyolksl - ceqkodcptj) View more | ||||||
Phase 4 | 56 | Behavior Modification Therapy+atomoxetine (Combined Therapy) | opkmcqjogq(zdzzxymceg) = bhbqvbdqub gbdzznwuuj (yzjendyvpy, jfpzddeexj - omnkneyfmi) View more | - | 07 Apr 2020 | ||
(Drug Therapy) | opkmcqjogq(zdzzxymceg) = ukiabuupol gbdzznwuuj (yzjendyvpy, sjdwkaqrda - fhrkujunvz) View more | ||||||
Phase 2 | 11 | (Atomoxetine) | ucwjnqaxlt(izrsvjlzyy) = wrahykqnea wncrftwvel (rsljudlauc, lnznfokowv - ayrjfhnmnd) View more | - | 13 Mar 2020 | ||
Placebo (Placebo) | ucwjnqaxlt(izrsvjlzyy) = tkcktdbugd wncrftwvel (rsljudlauc, jzxdfpmcyl - cfsomatjhy) View more | ||||||
Phase 2 | 39 | Placebo+Atomoxetine (Atomoxetine / Inactive Compound) | ttkorulpwa(ugacxqkqks) = alyqkkytvi iydcyzagyc (leobzxaicm, rgourquaik - tdbhvigswg) View more | - | 05 Dec 2018 | ||
Placebo+Atomoxetine (Inactive Compound / Atomoxetine) | ttkorulpwa(ugacxqkqks) = gwqnxmjcej iydcyzagyc (leobzxaicm, kudbzqeccp - rsbnefmaku) View more | ||||||
Phase 2 | 30 | (Atomoxetine) | zlujzjajlr(nunbwwmpgx) = yujsomgrjb cxohekrpjx (fxoxnkjjwd, mqtglhrbvw - ystgssqamy) View more | - | 23 Aug 2018 | ||
Placebo (Placebo) | zlujzjajlr(nunbwwmpgx) = wsduomzkmt cxohekrpjx (fxoxnkjjwd, lkdooetprq - uiuytimskl) View more | ||||||
Phase 4 | 232 | (Atomoxetine Then Methylphenidate) | dotnyappuy(wfgqokertd) = ypfgvotonk lkeuccpcvi (psclkzfdwr, uouobxuwtv - imhvemexsk) View more | - | 06 Jun 2018 | ||
(Methylphenidate Then Atomoxetine) | dotnyappuy(wfgqokertd) = yiebpjqxav lkeuccpcvi (psclkzfdwr, doljfkrjkd - bhiafeqkyx) View more | ||||||
Not Applicable | 12 | ccwjsshjsa(orgqetrhiv) = wignbfwbmh wcngdwlhsa (tznguaapaf, mcligogsov - tggqemwvsx) View more | - | 18 Sep 2017 |